The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Josh Sargent scores a second-half double to spark Norwich City to a win over Stoke City that revives their play-off hopes.
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
Norwich City are unbeaten across their past eight league games against Stoke City (W5 D3), scoring 3+ goals in four of those ...
The school leaders taking unprecedented action to ensure a safe learning environment with amenities in good working order ...
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Norwich comfortably saw off Stoke 4-2 at Carrow Road to record their first win in four matches and reignite their bid to ...
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...
tom's Hardware on MSN8d
TSMC and Intel rumors stoke Taiwanese fears of losing its 'Silicon Shield'When you buy through links on our articles, Future and its syndication partners may earn a commission.
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback